On May 16, 2023, Boundless Bio, a clinical-stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, announced the closing of a $100 million Series C financing. The financing was co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors Sectoral Asset Management and Piper Heartland Healthcare Capital. Wilson Sonsini Goodrich & Rosati advised Boundless Bio on IP matters related to the transaction.

The Wilson Sonsini team included Michael Hostetler, Deborah Smith, Alicia Umpierre, Céline Bonnefous, Jennifer Floyd, Erin Boyle Anderson, and Trevor Lyons.

For more information, please see Boundless Bio’s news release.